MTDH在浸润性乳腺癌不同分子亚型中的表达及临床意义

摘要

Objective:To examine MTDH expression in different molecular subtypes of invasive breast cancer and to investigate the correlation with clinicopathological parameters.Methods:Pathological specimens from 287 patients with invasive ductal carcinoma of breast cancer were examined by immunohistochemistry for ER,PR,Ki67,HER-2 and MTDH expression.Correlations between the expression of MTDH and various clinicopathological factors were ana-lyzed.Results:The positive rate of MTDH was 45 .99% in all invasive breast cancer patients.MTDH expression was correlated with tumor size,lymphatic venous invasion,lymph nodal metastasis and TNM stage.However,there was no statistical difference of MTDH expression in molecular subtypes of invasive ductal carcinoma.The rate of MTDH was highest in Basal-like subtype,it was 55.32%.Conclusion:MTDH expression was significantly in Basal -like sub-type ,MTDH perhaps was a novel target gene in therapy of Basal-like subtype which was not sensitive to endocrine-therapy and trastuzumab.%目的：检测MTDH基因在浸润性乳腺癌不同分子亚型中的表达情况，研究MTDH与分子分型的关系及临床意义。方法：通过免疫组化方法检测287例浸润性导管癌癌组织的ER、PR、Ki67、HER－2和MTDH的表达情况。然后分为不同分子亚型，统计分析MTDH在各亚型中的表达情况以及与临床病理因素的相关性。结果：287例浸润性导管癌中，Luminal A型70例，Luminal B型123例，HER－2阳性型47例，Basal －like 型47例。MTDH 总体高表达率为45．99％，亚型中分别为：Luminal A：31．43％，Luminal B：48．78％，HER－2＋：51．06％，Basal－like：55．32％。MTDH高表达与肿瘤大小、脉管浸润、腋窝淋巴结转移及TNM分期相关。结论：MTDH 在Basal－like型浸润性导管癌中高表达，为Basal－like型乳腺癌的治疗提供新的靶基因。